Close-up of senior black woman sorting weekly medication. Member of a black middle class America family. Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the ...

Boston, MA - A new study shows a significant reduction in the incidence of Alzheimer's disease and dementia among subjects taking angiotensin-receptor blockers (ARBs), compared with those taking ACE ...

Since the introduction of ARBs, the question that has pervaded each clinician’s mind is whether or not these drugs serve an advantage in conditions long addressed by ACE inhibitors. Matchar et al ...

Figure 3. ACE inhibitors and ARBs have different sites of action within the RAS pathway. The solid arrows indicate activation, and the dashed arrows indicate inhibition. ACE = angiotensin-converting ...

Blood pressure medications work in different ways to bring blood pressure to within an optimal range. Read on for more.

Angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) are recommended widely as first-line treatments for hypertension in patients with diabetic or nondiabetic ...

The European Medicines Agency (EMA) has issued a statement reiterating that people should continue to take certain blood pressure medicines during the COVID-19 pandemic. Recent observational studies, ...

Hypertension, commonly called high blood pressure, is one of the most widespread chronic conditions worldwide. It often develops without noticeable symptoms, yet it significantly increases the risk of ...

Many medications can help lower high blood pressure (hypertension), but no single one works best for everyone. The good news is, with some patience and help from your healthcare provider, you’ll ...

A meta-analysis suggests adverse events are often falsely attributed to BP-lowering drugs, leaving patients undertreated.

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...